Concord Biotech Ltd
NSE: CONCORDBIO | BSE: 543960
₹1,123.30
₹7.30
(0.65%)
As on 21-May-2026IST
Market cap
₹11,759 Cr
Revenue (TTM)
₹1,159 Cr
P/E Ratio
37.6
P/B Ratio
6.2
Div. Yield
1 %
Quality Score
8/10
Growth Score
6/10
Valuation Score
2/10
Momentum Score
3/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹313 Cr
-
ROE
22.3 %
-
ROCE
29.6 %
-
Industry P/E
37.35
-
EV/EBITDA
24.2
-
Debt to Equity
0
-
Book Value
₹180.8
-
EPS
₹30.1
-
Face value
1
-
Shares outstanding
104,616,204
10 Years Aggregate
CFO
₹1,330.38 Cr
EBITDA
₹2,721.03 Cr
Net Profit
₹1,913.56 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Concord Biotech
| -16.5 | 5.3 | 2.3 | -25.7 | -- | -- | -- |
|
BSE Healthcare
| 10.2 | 10.3 | 11.1 | 13.4 | 28.1 | 14.5 | 12.1 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Concord Biotech
| -37.4 | 49.4 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Concord Biotech
|
1,123.3 | 11,759.4 | 1,158.7 | 309.6 | 31.9 | 17.3 | 37.6 | 6.2 |
| 1,056.5 | 12,957.0 | 2,551.8 | 564.5 | 28.3 | 18.4 | 23 | 3.9 | |
| 440.0 | 7,618.6 | 1,053.1 | 293.6 | 32.3 | 24.6 | 26 | 5.9 | |
| 1,751.5 | 33,199.0 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.9 | 6.7 | |
| 357.1 | 3,891.2 | 159.3 | 47.8 | 39.0 | 18.6 | 81.4 | 14.1 | |
| 16,690.0 | 21,397.2 | 2,023.0 | 364.0 | 23.9 | 20.8 | 58.8 | 11.4 | |
| 2,274.2 | 3,757.0 | 707.5 | 115.2 | 17.8 | 19.4 | 32.6 | -- | |
| 1,109.4 | 5,101.4 | 649.5 | 121.6 | 23.7 | 13.2 | 44.2 | 5.5 | |
| 668.2 | 7,545.5 | 502.0 | 138.7 | -- | 32.8 | 43.6 | 8.7 | |
| 269.5 | 7,078.3 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 12.0 |
Shareholding Pattern
View DetailsNews & Analysis
All News
4 min read•By Vishal Goyal
About Concord Biotech
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in... immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. Read more
-
Incorporated
1984
-
Chairman
Sudhir Vaid
-
Managing Director
Sudhir Vaid
-
Headquarters
Ahmedabad Dist, Gujarat
-
Website
Looking for more details about Concord Biotech Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Concord Biotech
What is the current share price of Concord Biotech Ltd Today?
The share price of Concord Biotech Ltd is ₹1,123.30 (NSE) and ₹1,124.05 (BSE) as of 21-May-2026 IST. Concord Biotech Ltd has given a return of -25.75% in the last 1 years.
What is the current PB & PE ratio of Concord Biotech Ltd?
The P/E ratio of Concord Biotech Ltd is 37.63 times as on 21-May-2026, a 1 premium to its peers’ median range of 37.35 times.
The P/B ratio of Concord Biotech Ltd is 6.22 times as on 21-May-2026, a 164 premium to its peers’ median range of 2.36 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
47.19
|
9.67
|
|
2024
|
51.68
|
10.43
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
What is the 52 Week High and Low of Concord Biotech Ltd?
The 52-week high and low of Concord Biotech Ltd are Rs 2,150.40 and Rs 987.00 as of 21-May-2026.
What is the market cap of Concord Biotech Ltd?
Concord Biotech Ltd has a market capitalisation of ₹ 11,759 Cr as on 21-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Concord Biotech Ltd?
Before investing in Concord Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.